Anthracyclines (doxorubicin, daunorubicin, and idarubicin) are very effective chemotherapeutic drugs to treat many cancers; however, the development of multiple drug resistance (MDR) is one of the major limitations for their clinical applications. Nano-delivery systems have emerged as the novel cancer therapeutics to overcome MDR. Up until now, many anthracycline nano-delivery systems have been developed and reported to effectively circumvent MDR both in-vitro and in-vivo, and some of these systems have even advanced to clinical trials, such as the HPMA-doxorubicin (HPMA-DOX) conjugate. Doxil, a DOX PEGylated liposome formulation, was developed and approved by FDA in 1995. Unfortunately, this formulation does not address the MDR problem. In this comprehensive review, more than ten types of developed anthracycline nano-delivery systems to overcome MDR and their proposed mechanisms are covered and discussed, including liposomes; polymeric micelles, conjugate and nanoparticles; peptide/protein conjugates; solid-lipid, magnetic, gold, silica, and cyclodextrin nanoparticles; and carbon nanotubes.

中文翻译：

---

克服多重耐药性的蒽环类纳米递送系统：全面综述

蒽环类药物（阿霉素、柔红霉素和伊达比星）是治疗多种癌症的非常有效的化疗药物；然而，多重耐药性（MDR）的发展是其临床应用的主要限制之一。纳米递送系统已成为克服 MDR 的新型癌症疗法。迄今为止，许多蒽环类药物纳米递送系统已被开发并报道可在体外和体内有效规避MDR，其中一些系统甚至已进入临床试验，例如HPMA-阿霉素（HPMA-DOX） ）共轭。Doxil 是一种 DOX 聚乙二醇化脂质体制剂，于 1995 年开发并获得 FDA 批准。不幸的是，该制剂并不能解决 MDR 问题。在这篇全面的综述中，涵盖和讨论了十多种已开发的蒽环类纳米递送系统来克服 MDR 及其提出的机制，包括脂质体；聚合物胶束、缀合物和纳米颗粒；肽/蛋白质缀合物；固体脂质、磁性、金、二氧化硅和环糊精纳米颗粒；和碳纳米管。